Related Experiment Video
Updated: Sep 5, 2025
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Glioblastoma and Methionine Addiction
Mark L Sowers1,2, Lawrence C Sowers1,3
1Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA.
Abstract:
Glioblastoma is a fatal brain tumor with a bleak prognosis. The use of chemotherapy, primarily the alkylating agent temozolomide, coupled with radiation and surgical resection, has provided some benefit. Despite this multipronged approach, average patient survival rarely extends beyond 18 months. Challenges to glioblastoma treatment include the identification of functional pharmacologic targets as well as identifying drugs that can cross the blood-brain barrier. To address these challenges, current research efforts are examining metabolic differences between normal and tumor cells that could be targeted. Among the metabolic differences examined to date, the apparent addiction to exogenous methionine by glioblastoma tumors is a critical factor that is not well understood and may serve as an effective therapeutic target. Others have proposed this property could be exploited by methionine dietary restriction or other approaches to reduce methionine availability. However, methionine links the tumor microenvironment with cell metabolism, epigenetic regulation, and even mitosis. Therefore methionine depletion could result in complex and potentially undesirable responses, such as aneuploidy and the aberrant expression of genes that drive tumor progression. If methionine manipulation is to be a therapeutic strategy for glioblastoma patients, it is essential that we enhance our understanding of the role of methionine in the tumor microenvironment.
Insights
Glioblastoma tumors exhibit a dependency on methionine, an amino acid crucial for cell metabolism and tumor progression. Understanding methionine's role is vital for developing new glioblastoma treatments.
Area of Science:
- Neuro-oncology
- Cancer Metabolism
- Molecular Biology
Background:
- Glioblastoma is an aggressive brain cancer with poor patient survival rates, often exceeding 18 months despite standard treatments like chemotherapy (temozolomide), radiation, and surgery.
- Current glioblastoma treatment strategies face challenges in identifying effective drug targets and ensuring drugs can penetrate the blood-brain barrier.
- Research is exploring metabolic vulnerabilities unique to glioblastoma cells as potential therapeutic targets.
Purpose of the Study:
- To investigate the critical role of exogenous methionine dependency in glioblastoma.
- To evaluate the potential of targeting methionine metabolism as a therapeutic strategy for glioblastoma.
- To elucidate the complex interactions between methionine, the tumor microenvironment, and glioblastoma progression.
Main Methods:
- Review of current research on glioblastoma metabolism and therapeutic targets.
- Analysis of the biochemical pathways involving methionine in cancer cells.
- Exploration of potential therapeutic interventions targeting methionine availability or utilization.
Main Results:
- Glioblastoma tumors display a significant reliance on exogenous methionine.
- Methionine plays a multifaceted role, influencing tumor microenvironment, epigenetic regulation, and cell division (mitosis).
- Potential therapeutic strategies like methionine dietary restriction require a deeper understanding due to complex consequences.
Conclusions:
- Methionine dependency presents a potential therapeutic target for glioblastoma.
- Further research is essential to fully understand methionine's role in the glioblastoma microenvironment before clinical application.
- Targeting methionine metabolism may offer a novel approach to glioblastoma treatment, but requires careful consideration of downstream effects.
More Related Videos
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
